{
    "nctId": "NCT04099277",
    "briefTitle": "A Study of LY3435151 in Participants With Solid Tumors",
    "officialTitle": "A Phase 1a/1b Study of LY3435151 Administered to Patients With Advanced Solid Tumors",
    "overallStatus": "TERMINATED",
    "conditions": "Solid Tumor, Triple-negative Breast Cancer, Gastric Adenocarcinoma, Head and Neck Squamous Cell Carcinoma, Cervical Carcinoma, High Grade Serous Ovarian Carcinoma, Hepatocellular Carcinoma, Undifferentiated Pleomorphic Sarcoma, Leiomyosarcoma",
    "studyType": "INTERVENTIONAL",
    "phase": "PHASE1",
    "allocation": "NON_RANDOMIZED",
    "primaryPurpose": "TREATMENT",
    "enrollmentCount": 2,
    "primaryOutcomeMeasure": "Number of Participants With LY3435151 Dose-Limiting Toxicities (DLTs)",
    "eligibilityCriteria": "Inclusion Criteria:\n\n* Participant must have certain types of cancer, which your study doctor will discuss with you\n* Participant must have stopped other forms of treatment for cancer, which your study doctor will discuss with you\n* Participant must be able and willing to provide a sample of your tumor before beginning treatment and once while on treatment. For certain tumor types, the outcome of the biopsy may exclude you from the study treatment (for Phase 1b)\n* Participant must agree to use birth control\n* Participant must have progressed through or are intolerant to therapies with known clinical benefit, which your study doctor will discuss with you\n\nExclusion Criteria:\n\n* Participant must not have a history of tuberculosis, uncontrolled HIV or uncontrolled hepatitis B or C virus infection\n* Participant must not have an autoimmune disease, which your study doctor will discuss with you\n* Participant must not use corticosteroids, which your study doctor will discuss with you\n* Participant must not have heart disease, Crohn's disease or brain cancer\n* Participant must not be pregnant or breastfeeding",
    "sex": "ALL",
    "minimumAge": "18 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}